Sign in

Trial result ·

Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc).

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This report covers 8 patients with severe juvenile-onset systemic sclerosis (JSSc). JSSc is a rare autoimmune disease. It harms blood vessels and many organs. Their disease had not responded to other drugs. All 8 had a stem cell transplant (ASCT) at one center. Checks were done every 6 months for up to 48 months.

What they found

Treatment led to no deaths and no organ toxicity. All patients engrafted. No patient died or had heart-lung failure or a kidney crisis. Median follow-up was 30 months. Skin scores improved, and so did walk distance. All stopped immune-suppressing drugs for at least 18 months. 1 patient later needed them again for a flare. Both patients with lung hypertension had normal lung pressures. Gut symptoms improved in most patients.

What it means for patients

The authors say ASCT was safe and well tolerated. They say it gave lasting gains across many body systems. They say the findings back earlier thought of ASCT for progressive, treatment-resistant disease.

Why it is not certain yet

Only 8 patients took part. They were treated at a single center. The abstract describes no comparison group. Median follow-up was 30 months.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc).

PubMed · PMID 42309868

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Systemic sclerosis (scleroderma) publications